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https://doi.org/1Background: Many patients undergoing durable left ventricular assist device (LVAD) implantation suffer
from chronic kidney disease (CKD). Therefore, we investigated the effect of LVAD support on CKD.
Methods: A retrospective multicenter cohort study, including all patients undergoing LVAD (HeartMate
II (n = 330), HeartMate 3 (n = 22) and HeartWare (n = 48) implantation. In total, 227 (56.8%) patients were
implanted as bridge-to-transplantation; 154 (38.5%) as destination therapy; and 19 (4.7%) as bridge-to-
decision. Serum creatinine measurements were collected over a 2-year follow-up period. Patients were
stratified based on CKD stage.
Results: Overall, 400 patients (mean age 53 § 14 years, 75% male) were included: 186 (46.5%) patients
had CKD stage 1 or 2; 93 (23.3%) had CKD stage 3a; 82 (20.5%) had CKD stage 3b; and 39 (9.8%) had
CKD stage 4 or 5 prior to LVAD implantation. During a median follow-up of 179 days (IQR 28627),
32,629 creatinine measurements were available. Improvement of kidney function was noticed in every pre-
operative CKD-stage group. Following this improvement, estimated glomerular filtration rates regressed to
baseline values for all CKD stages. Patients showing early renal function improvement were younger and
in worse preoperative condition. Moreover, survival rates were higher in patients showing early improve-
ment (69% vs 56%, log-rank P = 0 .013).
Conclusions: Renal function following LVAD implantation is characterized by improvement, steady state
and subsequent deterioration. Patients who showed early renal function improvement were in worse preop-
erative condition, however, and had higher survival rates at 2 years of follow-up. (J Cardiac Fail
2020;26:333341)
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333Introduction
Left ventricular assist devices (LVADs) have become an
accepted treatment modality for patients with end-stage
heart failure (HF).1 Patients with end-stage HF commonly
suffer from end-organ dysfunction, including chronic kid-
ney disease (CKD), which is often attributed to the cardi-
orenal syndrome.2 Cardiorenal syndrome type 2, renal
dysfunction caused by a number of factors, including high
central venous pressures and insufficient cardiac output, fre-
quently hampers the quality of life of these patients.3 They
are at risk of developing end-stage renal disease and have
higher rates of mortality following LVAD implantation.4-6
Several studies have reported that after LVAD implanta-
tion, mean renal function improves within the first month.2,7
However, this mean increase seems to be largely of a tran-
sient nature because mean renal function deteriorates subse-
quent to the improvement. This was largely confirmed by
334 Journal of Cardiac Failure Vol. 26 No. 4 April 2020Brisco et al when they analyzed the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS).2
They noticed a marked improvement of mean renal function
following LVAD implantation and a subsequent deterioration
of renal function. The mechanisms of why and how some
patients’ renal functions improve and why most patients’ sub-
sequently deteriorate has yet to be elucidated. Subsequently, it
was hypothesized that perhaps intrinsic renal injury, continu-
ous-flow physiology, hemolysis, and neurohormonal activity
could be the reasons for this deterioration. Importantly, how-
ever, their methodology of depicting renal function is limited
by the use of means at set points in time and their restricted
follow-up period. This methodology favors the renal function
of survivors and, therefore, may not depict accurately the
evolution of renal function. There is a great demand for longi-
tudinal assessment of renal function following LVAD implan-
tation. Therefore, the aim of this study was to investigate the
impact of prolonged LVAD support on changes in renal func-
tion and to identify patient-related factors associated with renal
function improvement following LVAD implantation.Methods
Study Design
We retrospectively reviewed all patients who received an
LVAD between October 2004 and April 2017 in the Eras-
mus MC, University Medical Center Rotterdam, the Nether-
lands; Johns Hopkins Hospital, Baltimore, USA; and the
Medical University Hospital, Charleston, South Carolina,
USA. Patients with missing data regarding preoperative
and/or postoperative serum creatinine were not included in
the analysis (N = 34). The study was approved by the insti-
tutional review boards of all participating centers. Patients
were classified into 4 groups based on their preoperative
CKD stages. Stages 1 and 2 and stages 4 and 5 were com-
bined into 1 group (see Supplementary Table 1 for the Kid-
ney Disease Improving Global Outcomes CKD stages).8
The primary study outcome was 1) quantification of the
evolution of the kidney function and 2) the factors associ-
ated with (sustained) renal function improvement during
the first 2 years following LVAD implantation by using lon-
gitudinal data. The secondary outcomes included all-cause
mortality and the association between renal improvement
and mortality. Patients were censored at the time of death,
heart transplantation or explantation of the LVAD.Data collection
All data were obtained from patients’ electronic records.
Baseline laboratory values were collected preoperatively for all
patients. Devices included were HeartMate II, Heartmate 3
(Abbott, Chicago, IL, USA) and HeartWare (HeartWare Inter-
national, Miami Lakes, FL, USA). Kidney function was defined
as the estimated glomerular filtration rate (eGFR), which was
measured regularly during outpatient clinic visits. Samples of
serum creatinine were collected over a 2-year period to
calculate eGFRs. To validate the calculated eGFRs, theChronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula was used.9 This formula is GFR = 141
* min(Scr/k,1)a * max(Scr/k, 1)-1.209 * 0.993Age * 1.018
(if female) * 1.159 (if black). Renal replacement therapy
after LVAD implantation was defined as the start of either
continuous veno-venous hemofiltration or intermittent
hemodialysis. Patients were not excluded if they had
received continuous veno-venous hemofiltration or hemo-
dialysis before or at the time of LVAD implantation. Early
( 70 days) renal function improvement was defined by
either an increase of  10 mL/min/1.73m2 of eGFR or as a
 50% increase of baseline eGFR within 3 months follow-
ing implantation. Sustained renal function was defined by
maintaining the early improvement following LVAD
implantation beyond 12 months.Statistical Analysis
Continuous parameters are expressed as mean and stan-
dard deviation or median interquartile range (IQR) accord-
ing to distribution and are compared with 1-way ANOVA,
the Student t test or the Mann-Whitney U test. Continuous
parameters were tested for normal distribution with the Sha-
piro-Wilk test. Categorical parameters are expressed as
number and percentage and compared by the x2 test or the
Fisher exact test. Kaplan-Meier curves stratified by preoper-
ative CKD stage were constructed for the evaluation of
mortality in the first 2 years postimplantation. Differences
pooled over strata were compared by the log-rank test
Continuous repeated measurement data were analyzed
using mixed models. Flexibility over time was established
using natural splines. In total, 3 internal knots seemed suffi-
cient upon graphic analyses (Supplementary Fig. 1) (Visuali-
zation of subject-specific prediction of 9 randomly chosen
patients of a model containing time with a spline function
using 4 knots (red line) and a model containing 3 knots (blue
line)). Included random effects were intercepts for patients
with random slopes for time. Two models were developed:
the first contained only time since implant; the second con-
tained time since implant and CKD stage, with their interac-
tion term. The t tests were used to compare point estimates of
CKD stage, as derived from the model. The models were
visualized by effect plots. Mixed modeling analyses were
done in R, version 3.3.3, with packages lme4 and emmeans
(R Foundation for Statistical Computing, Vienna, Austria).10Results
Baseline characteristics
In total, 400 patients were included (75% male, mean age 53
§ 14 years); 84 (21%) patients from the Erasmus MC Univer-
sity Medical Center, 224 (56%) patients from Johns Hopkins
Hospital, and 92 (23%) patients from the Medical University of
South Carolina. The Heartmate II device was the most fre-
quently implanted: 330 (82%); followed by the HeartWare
device: 48 (12%); and 22 (6%) patients received a HeartMate 3
device. The baseline characteristics of the 4 groups are
Table 1. Baseline Characteristics of Patients With Preoperative CKD Undergoing LVAD Implantation
Variables
All patients
(N = 400)
CKD stage 1 and 2
(n = 186)
CKD stage 3a
(n = 93)
CKDstage 3b
(n = 82)
CKD stages 4 and 5
(n = 39) P value
Age <0.001
< 45 99 (25) 69 (37) 18 (19) 8 (10) 4 (10)
4554 84 (21) 44 (24) 17 (18) 19 (23) 4 (10)
5564 147 (37) 57 (30) 40 (43) 33 (40) 17 (44)
 65 70 (17) 16 (9) 18 (19) 22 (27) 14 (36)
Male gender 298 (75) 125 (67) 74 (80) 68 (83) 31 (80) 0.02
BMI 26 (2331) 26 (2231) 26 (2332) 26 (2033) 28 (2533) 0.51
Ischemic
cardiomyopathy
139 (35) 51 (27) 35 (38) 36 (44) 17 (44) 0.03
Diabetes mellitus 157 (39) 73 (39) 31 (33) 31 (39) 22 (56) 0.1
Hypertension 186 (47) 78 (42) 50 (54) 39 (48) 19 (47) 0.3
ICD/PM 326 (82) 139 (75) 81 (87) 69 (84) 37 (95) 0.01
TIA or CVA 66 (17) 32 (17) 14 (15) 13 (16) 7 (18) 0.97
Destination therapy 154 (39) 58 (31) 35 (38) 39 (48) 22 (56) 0.14
IABP 133 (33) 63 (34) 24 (26) 33 (40) 13 (33) 0.25
ECMO 20 (5) 13 (7) 3 (3) 4 (5) 0 0.24
Inotropic support 323 (81) 156 (84) 71 (76) 67 (83) 29 (78) 0.45
INTERMACS
(n = 384)
0.67
Profile 1 67 (17) 38 (20) 11 (13) 13 (17) 5 (14)
Profile 2 120 (30) 53 (29) 27 (30) 27 (36) 13 (37)
Profile 3 135 (34) 66 (36) 35 (39) 24 (32) 10 (29)
Profile  4 62 (16) 28 (15) 16 (18) 11 (15) 7 (20)
Device type 0.02
HM 2 330 (82) 162 (87) 74 (80) 61 (74) 33 (85)
HM 3 22 (6) 3 (2) 6 (6) 9 (11) 4 (10)
HW 48 (12) 21 (11) 13 (14) 12 (15) 2 (5)
Laboratory values
eGFR mL/min/1.73 m2 57 (4279) 81 (6997) 52 (4856) 39 (3342) 24 (2127) < 0.001
Creatinine mg/dL 1.40 (1.091.79) 1.09 (0.91.19) 1.50 (1.401.65) 1.95 (1.702.10) 2.70 (2.393.09) < 0.001
Blood urea nitrogen
mg/dL
28 (1942) 22 (1630) 30 (2442) 35 (2850) 48 (3663) < 0.001
Sodium mmol/L 136 (132139) 135 (131138) 136 (132139) 136 (133140) 136 (132138) 0.56
Bilirubin mg/dL 1,1 (0,71,8) 1,1 (0,61,6) 1,1 (0,82,5) 1,1 (0,71,7) 1,2 (0,81,7) 0.12
HR denotes hazard ratio.
CI, confidence interval; CKD, chronic kidney disease; CVA, cerebrovascular accident; ECMO, extracorporeal membrane oxygenation; eGFR, estimated
glomerular filtration rate; HM II, Heartmate II; HM 3, Heartmate 3; HW, HeartWare; IABP, intra-aortic balloon pump; ICD, implantable cardioverter defibril-
lator; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device; PM, pace maker; TIA, tran-
sient ischemic attack.
Chronic kidney disease post LVAD  Yalcin et al 335presented in Table 1. Stratified according to preoperative CKD
stages, 186 (46.5%) patients had CKD stages 1 or 2; 93
(23.3%) patients had CKD stage 3a; 82 (20.5%) patients had
CKD stage 3b; and 39 (9.8%) patients had CKD stage 4 or 5.
Patients with preoperative CKD stages of 1 or 2 were younger
(P < 0.001), more commonly had nonischemic etiologies of
their cardiomyopathy (P = 0.03) and had lower rates of implant-
able cardioverter-defibrillators or pacemakers (P = 0.02).Evolution of eGFR
During the 2 years following LVAD implantation, 32,629
measurements of eGFR were collected: CKD stage 1 or 2
group: 15,760 (48.3%); CKD stage 3a group: 7202 (22%);
CKD stage 3b group: 6854 (21%); CKD stage 4 or 5 group:
2813 (8.6%). The mean number of serum creatinine measure-
ments per patient was 82§ 43. The general evolution of eGFR
for all patients is plotted in Fig. 1a. Model summary is pre-
sented in Supplementary Table 2a (Supplement: Model sum-
mary depicting the individual time points used to determine the
p-values (compared to time = 0, and in table 2b, compared to
CKD stages 1 and 2) of the of the mixed model Figs. 1 and 2).The greatest improvement in kidney function was noted at
90 days post LVAD implantation. In addition, kidney function
did not differ from baseline at day 210, and the nadir was noted
at day 455, after which kidney function plateaued.
Fig. 1b depicts the evolution of eGFR stratified by preop-
erative CKD stage. Model summary is presented in Supple-
mentary Table 2b (Supplement: Model summary depicting
the individual time points used to determine the p-values
(compared to time = 0, and in table 2b, compared to CKD
stages 1 and 2) of the of the mixed model Figs 1 and 2). The
mean improvement of eGFR at 70 days is 14% in CKD
stages 1 and 2, 25% in CKD stage 3a, 29% in CKD stage 3b,
and 83% in CKD stages 4 and 5. This improvement remained
significant up to day 150 following LVAD implantation for
CKD stages 3a, 3b, 4, and 5. Following the first 150 days, all
CKD stages regressed toward their respective baselines.
None of the preoperative CKD stages remained significantly
improved compared to baselines. After 1 year of follow-up,
the kidney function reached a plateau comparable to that of
the baseline kidney function. Following the 1-year follow-up
mark, no significant changes (ie, improvement or deteriora-
tion) were noticed compared to baseline.
Fig. 1. a, Advanced mixed modeling illustrating the evolution of overall eGFR over 2 years of follow-up (central illustration). b, Advanced
mixed modeling illustrating the evolution of eGFR over 2 years of follow-up, stratified by preoperative CKD stage. CKD, chronic kidney
disease; eGFR, estimated glomerular filtration rate.
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Early renal function improvement was experienced by
230 (57%) of the patients, whereas 160 (40%) experienced
no early renal improvement or early renal deterioration, and
10 (3%) patients had missing follow-up until day 70. Thepatients showing early renal improvement were divided as
follows: 96 (53.3%) patients were in CKD stages 1 or 2; 56
(61.5%) patients were in CKD stage 3a; 48 (58.5%) were in
CKD stage 3b; and 30 (81.1%) were in CKD stage 4 or 5
(P = 0.018). Patients who experienced early renal function
Chronic kidney disease post LVAD  Yalcin et al 337improvement were younger in age, had lower mean baseline
eGFRs and were more often implanted as bridge-to-trans-
plant than as destination therapy. Additionally, patients
showing early renal function improvement had higher needs
for intra-aortic balloon pump support and had overall lower
INTERMACS scores (ie, profile 1 or 2) prior to LVAD
implantation. The need for extracorporeal membrane oxy-
genation and the need for inotropic support had no effect on
renal function improvement. All baseline characteristic dif-
ferences are noted in Table 2.
Sustained renal function improvement was observed in
53 (13.2%) patients. Differences in patients with sustained
renal function improvement were younger in age (47 §
14 vs 53 § 13, P = 0.001), had higher eGFRs (65 § 27 vs
55 § 24, P = 0.02) and had less preoperative diabetes
(22.6% vs 41.2%, P = 0.01).
Thereafter, a subset of the cohort was analyzed with pre-
operative (maximum of 30 days prior to implantation) right
heart catheterization (RHC) measurements (n = 300)
(Table 3a and 3b). No significant differences in preoperativeTable 2. Differences in Baseline Characteristics in Patients who
Experienced Renal Function Improvement or not After LVAD
Implantation
Variables
Improvement
(n = 230)
No
improvement
(n = 160) P value
Age 0.02
< 45 65 (28) 29 (18)
4554 43 (19) 41 (26)
5564 89 (39) 55 (34)
 65 33 (14) 35 (22)
Male gender 166 (72) 123 (77) 0.3
BMI 26 (23-31) 27 (23-32) 0.23
Ischemic
Cardiomyopathy
76 (33) 62 (39) 0.25
Diabetes mellitus 85 (37) 70 (44) 0.18
Hypertension 107 (47) 76 (48) 0.85
ICD/PM 190 (83) 132 (83) 0.98
TIA or CVA 39 (17) 27 (17) 0.99
Destination therapy 78 (34) 72 (45) 0.03
IABP 89 (39) 40 (25) 0.005
ECMO 8 (4) 10 (6) 0.2
Inotropic support 184 (80) 131 (82) 0.68
INTERMACS 0.003
Profile 1 32 (15) 31 (20)
Profile 2 81 (37) 36 (23)
Profile 3 68 (31) 66 (42)
Profile  4 36 (17) 25 (15)
Device type 0.08
HM II 186 (81) 135 (84)
HM 3 26 (11) 21 (13)
HW 18 (8) 4 (3)
Laboratory values
eGFR, mL/min/1.73m2 53 (4172) 65 (4487) < 0.001
Creatinine mg/dL 1.47 (1.191.94) 1.30 (0.991.67) 0.005
Bilirubin mg/dL 1.2 (0.71.8) 1.1 (0.61.8) 0.73
HR denotes hazard ratio.
BMI, body mass index; CI, Confidence interval; CKD, chronic kidney
disease; CVA, cerebrovascular accident; IABP, intra-aortic balloon pump;
ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomeru-
lar filtration rate; HM II, Heartmate II; HM 3, Heartmate 3; HW, Heart-
Ware; ICD, implantable cardioverter defibrillator; INTERMACS,
Interagency Registry for Mechanically Assisted Circulatory Support; PM,
pace maker; TIA, transient ischemic attack.RHC measurements between the preoperative CKD stages
were observed. Comparing patients who experienced early
renal function improvement to those who did not experience
improvement resulted in the following differences: patients
who experienced early renal function improvement had
lower preoperative cardiac indexes, higher mean right arterial
pressures, higher right ventricular diastolic pressures, higher
pulmonary artery diastolic pressures, and higher pulmonary
capillary wedge pressures.
Clinical course
Overall, 175 patients (44%) died during the first 2 years of
follow-up. Stratified by CKD stage, the median follow-up time
was 244 (34710) days for CKD stages 1 and 2; 121 (24481)
days for CKD stage 3a; 141 (204593) days for CKD stage 3b;
and 103 (24409) days for CKD stages 4 and 5. The 2-year
overall survival rate (Fig. 2) in these respective groups was
58.1% vs 54.8% vs 58.5% vs 46.2% (log-rank:
P < 0.001). The Kaplan-Meier curves of 5-year survival are
provided in Supplementary Fig. 2 (Kaplan Meier Curve based
on pre-operative CKD stage, illustrating the differences in
5-year survival stratified by preoperative CKD stages). Further-
more, patients with higher CKD stages required renal replace-
ment therapy more commonly following LVAD implantation:
12% in CKD stages 1 and 2; 22%, 22% and 39% in CKD stages
3a, 3b, 4, and 5 (log-rank: P< 0.001), respectively. Fig. 3 com-
pares the 2-year survival rates of patients who did (69; 5%) and
did not (56; 2%) experience early renal function improvement
(log-rank: P = 0.013), respectively. Finally, patients with sus-
tained renal function improvement were identified (n = 53).
Patients with sustained renal function improvement were youn-
ger in age (P = 0.01), had lower rates of diabetes mellitus
(P = 0.01), had higher baseline eGFRs (P = 0.01), and had
higher mean diastolic pulmonary pressures (P = 0.02).
Discussion
The current study evaluated the impact of prolonged
LVAD therapy on kidney function. Our principal findings
are as follows. 1) Following LVAD therapy, all patient
groups (in all preoperative CKD stages) experienced signifi-
cant early mean renal function improvement and subsequent
regression to baseline. At 1 year of follow-up, all patient
groups had mean renal function similar to their respective
mean baseline eGFRs. 2) Patients who experienced early
renal function improvement were younger, had higher pre-
operative CKD stages, lower INTERMACS scores and
worse hemodynamic profiles. 3) Patients who experienced
early renal function improvement had higher 2-year sur-
vival rates than patients who did not experience improve-
ment. These results underline the transient nature of renal
function improvement in all preoperative CKD stages.
However, despite the observed transient nature, early renal
function improvement is associated with higher survival
rates at 2 years of follow-up.
The next step in personalized medicine is considering and
examining all available data. The appropriate methodology to
Table 3a. Baseline Right Heart Catheterization Measurements (n = 300) for Each of the Preoperative CKD Stages
Variables
All patients
(N = 300)
CKD stages 1
and 2 (n = 141)
CKD stage 3a
(n = 68)
CKD stage 3b
(n = 61)
CKD stages 4
and 5 (n = 30) P value
Cardiac output (thermodilution L/min) 3.6 § 1.1 3.6 § 1.2 3.4 § 1.1 3.6 § 1 3.5 § 1.2 0.71
Cardiac index (L/min/m2) 2.7 § 1.6 2.7 § 1.5 2.7 § 1.7 3 § 1.9 2.1 § 1.2 0.14
Right atrial pressure (mmHg) 13.1 § 6.9 13.0 § 7.0 12.8 § 6.4 12.6 § 6.0 15.6 § 9 0.23
Right ventricular systolic pressure
(mmHg)
53 § 14.8 51.0 § 14.5 52.5 § 15.6 56.6 § 13.8 56.3 § 15.8 0.09
Right ventricular diastolic pressure
(mmHg)
12.7 § 6.8 12.8 § 7.4 12.6 § 6.3 12.3 § 5.6 13.3 § 7.4 0.93
Pulmonary artery pressure (mmHg) 37 § 10.3 36.1 § 11.1 37.7 § 10.3 37.2 § 8.5 39.0 § 9.7 0.22
Pulmonary artery systolic pressure
(mmHg)
53.8 § 14.9 52.0 § 15.4 54.2 § 15.0 55.9 § 13.7 56.7 § 14.4 0.89
Pulmonary artery diastolic pressure
(mmHg)
28.0 § 8.8 27.7 § 9.6 28.4 § 8.4 27.7 § 7.5 28.9 § 8.5 0.48
Pulmonary capillary wedge pressure
(mmHg)
25.9 § 8.8 25.8 § 9.9 26.4 § 8.5 25.2 § 6.4 26.7 § 8.5 0.85
CKD, chronic kidney disease.
338 Journal of Cardiac Failure Vol. 26 No. 4 April 2020depict changes accurately takes all individual measurements
into consideration. This allows for the use of mixed-modeling
analyses depicting more accurate evolutions. This novel
approach adjusts both the correlation among patients and the
correlation among measurements in the same patient. More-
over, it adjusts, to a certain degree, for missing data and mor-
tality. This methodology yields the most accurate depiction of
renal function evolution following LVAD implantation.The differing phases of renal function
We confirm that the evolution of renal function can be
divided into 3 phases. The first phase is characterized by a
marked improvement in renal function, which is proportion-
ally greater in patients with higher CKD stages. This phase
transpires in the first 70 days following LVAD implantation.
Improvement of renal function is most likely driven by
improved cardiac output and relief of venous congestion. In
patients with HF, venous congestion is 1 of the major factors
that drive worsening renal function.11 Indeed, our results
show that patients with higher preoperative right atrial pres-
sures, which are closely linked to central venous pressures,
were more likely to show early renal function improvement.
The second phase marks renal recovery. This phase starts
after the renal improvement phase and concludes at approx-
imately 150 days of follow-up. This phase represents anTable 3b. Differences in Right Heart Catheterization Measurement
Improvement and Those w
Variables Renal improvement at 70 day
Cardiac output (thermodilution L/min) 3.5 § 1.2
Cardiac index (L/min/m2) 2.5 § 1.5
Right atrial pressure (mmHg) 14.0 § 7.2
Right ventricular systolic pressure (mmHg) 52.2 § 14.5
Right ventricular diastolic pressure (mmHg) 13.6 § 7.3
Pulmonary artery pressure (mmHg) 38.0 § 9.8
Pulmonary artery systolic pressure (mmHg) 55.0 § 14.6
Pulmonary artery diastolic pressure (mmHg) 29.1 § 8.4
Pulmonary capillary wedge pressure (mmHg) 27.0 § 8.9opportunity to maintain the regained function from the first
phase for as long as possible, perhaps by adjusting the
LVAD parameters to provide optimal output, by closely
monitoring the fluid status, and by monitoring and optimiz-
ing right ventricle (RV) function.
Finally, the deterioration phase sets in. This phase is noticed
in all baseline CKD stages, suggesting multifactorial determi-
nants, and it could be inherent in contemporary LVAD therapy.
Because it is the most poorly understood phase, various
hypotheses have been proposed. One postulated mechanism
for renal function deterioration is the worsening of RV func-
tion. Longitudinal studies have yielded mixed conclusions con-
cerning this phenomenon, with some showing improvement in
RV function over time and others the opposite.12,13 Unfortu-
nately, the effects of postoperative RV dysfunction or failure of
kidney function in patients after LVAD remain poorly under-
stood.14 Other postulated mechanisms include dysregulation of
the baroreceptors, local upregulation of the renin-angiotensin
system and possible hyperfiltration.1517 Additionally, shear
stress caused by the mechanical suction (inducing hemolysis)
could cause chronic renal ischemia, nephrotoxicity and proa-
poptosis of renal tubular epithelial cells.18 Last, the prolonged
use of anticoagulation, in the form of warfarin, may be associ-
ated with the onset of anticoagulant-related nephropathy.19 Pro-
spective studies are necessary to elucidate the delicate
mechanisms behind renal function deterioration.s (N = 300) Between Patients who Show Early Renal Function
ho Do not Improve
s (n = 160) No renal improvement at 70 days (n = 140) P value
3.6 § 1.1 0.97
3.0 § 1.8 0.02
12.0 § 6.6 0.01
52.0 § 15.3 0.25
11.7 § 6.2 0.02
35.8 § 10.8 0.06
52.6 § 15.3 0.17
26.7 § 9.0 0.02
24.5 § 8.7 0.02
Fig. 2. Kaplan-Meier survival curve based on preoperative CKD stages, illustrating the differences in 2-year survival stratified by preopera-
tive CKD stages. CKD, chronic kidney disease.
Fig. 3. Kaplan-Meier survival curve based on postoperative early renal function improvement, illustrating the differences in survival.
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Unfortunately, not all individuals experience renal func-
tion improvement following LVAD implantation. We found
early improvement present in 59% of patients. These patients
were younger, were implanted under worse conditions (ie,
needing intra-aortic balloon pump support, overall lower
INTERMACS scores and worse hemodynamic profiles) and
had worse preoperative renal function. The findings are con-
sistent with a group of patients with type 2 cardiorenal syn-
drome.3 Interestingly, subsequent survival rates were higher
in patients experiencing early renal function improvement,
despite its transient nature. Renal function improvement was
linked with superior outcomes compared to those with no
improvement, regardless of LVAD implantation indication
(Supplementary Material 5) (Competing outcomes analysis).
This distinction is of paramount importance because of the
increasing number of candidates for LVAD who are
implanted when they have acute renal dysfunction, cardio-
genic shock and seemingly worse renal function. Last, sus-
tained renal function improvement was observed in 13% of
all implanted patients. Older patients with diabetes and worse
preoperative renal function were more commonly associated
with nonsustained renal function improvement. Evidently,
earlier studies reported that preoperative proteinuria (often
seen in patients with diabetes) is independently associated
with an increase in renal replacement therapy and worse sur-
vival rates.5,6 This finding alludes to intrinsic preoperative
renal damage, most likely caused by diabetic nephropathy.
More research is needed to further elucidate factors associ-
ated with sustained renal function following LVAD implan-
tation.Clinical perspectives
The trend of eGFRs after LVAD implantation displays an
initial improvement of overall mean eGFRs. However, subse-
quent to this improvement, a regression in overall mean eGFR
to the baseline is noticed in all patient groups, regardless of
eGFR function prior to LVAD implantation. Nonetheless,
early renal function improvement is associated with better sur-
vival rates following LVAD implantation. Therefore, sole
severe renal dysfunction (eGFR< 45) should not exclude can-
didacy for LVAD implantation. Selection criteria should
include age, the primary presentation, the setting of LVAD
implantation (emergent or elective), the baseline renal func-
tion, and concomitant hemodynamic profile (renal venous con-
gestion and/or forward failure). Those with the most severe
hemodynamic derangements are most likely to benefit. Addi-
tional research is warranted to identify which factors predict
sustained renal function improvement post LVAD implanta-
tion and what the underlying mechanisms are.Strengths and limitations
There are a number of limitations that should be taken into
consideration when interpreting our findings. First, due to the
retrospective study design, causality cannot be established.Second, the group with CKD stages 4 or 5 consisted of a rela-
tively small number of patients, possibly affecting the out-
come of the analysis by overestimating their survival. Third,
this cohort consisted mostly of INTERMACS class 1 and 2
patients, which has resulted in a rather higher 2-year mortal-
ity rate. This may have affected the evolution of renal func-
tion. Fourth, not all patients had RHC data 30 days prior to
LVAD implantation. To uphold the predictive value of the
measurements, only the 300 patients with prior 30-day RHC
data could be analyzed. This should be taken into consider-
ation when reading the results. Fifth, clinicians were not
blinded to changes in renal function and treated patients
accordingly, thereby possibly altering the clinical outcomes.
Sixth, the lack of postoperative hemodynamic measurements
hindered our ability to associate late hemodynamic profile
changes with renal function deterioration. Last, using serum
creatinine-based GFR estimations in a population suffering
from muscle wasting and subsequent gain of muscle after
LVAD implantation can over- and/or underestimate the
impact of changes in serum creatinine. Unfortunately, no
other renal function estimation biomarkers, such as cystatin
C or 24-hour urine creatinine clearance, were available.
However, due to the longitudinal approach, instead of using
means over set points in time, a more accurate evolution of
renal function was possible. In addition, in our opinion, the
inclusion of all available contemporary types of LVADs and
multicenter, transatlantic patients strengthens the conclusions
and generalizability of this study.Conclusions
Renal function following LVAD implantation shows a
triphasic pattern characterized by significant early improve-
ment, a period of steady-state function and subsequent dete-
rioration to baseline. Patients with early renal function
improvement were younger and had worse preoperative
conditions and CKD stages but had better survival rates at
long-term follow-up.Disclosures
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